“Turning down the volume” of a faulty gene in heart disease

Twelve years ago, then-assistant professor of cardiovascular medicine, Euan Ashley sat in his new office, contemplating an idea.

Read on to hear how Euan, now Chairman of the SVEXA Board, and his colleagues at Stanford have pioneered a technique to address cardiomyopathy using 'RNA silencing' to adjust genomic underpinnings of a disease to restore normal function.